<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879775</url>
  </required_header>
  <id_info>
    <org_study_id>E00058</org_study_id>
    <secondary_id>GR0857-006</secondary_id>
    <secondary_id>SuYeon2009-08</secondary_id>
    <nct_id>NCT00879775</nct_id>
  </id_info>
  <brief_title>Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain</brief_title>
  <official_title>Efficacy of Caffeine as an Adjuvant to Opioid Therapy in Cancer Pain: a Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain is a most common symptom and it has a high impact on quality of life in cancer patients.
      Many cancer patients have received opioid therapy, but also many of them have suffered from
      side effects of opioids. Drowsiness and confusion are common side effects of opioids.
      Caffeine is a well known psychostimulant,and it is widely used as an analgesics. Thus, the
      investigators aimed to prove the efficacy of intravenous caffeine administration as an
      adjuvant analgesics to opioids. At the same time, the investigators tried to find that the
      side effects of opioids could be ameliorated by caffeine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies on cancer pain lacked assessment of quality of life. And most of previous
      studies on cancer pain did not give attention to symptoms accompanied with pain. We include
      such variables as outcome measures, and aimed to evaluate the efficacy and the safety of
      intravenous caffeine in advanced cancer inpatients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids</measure>
    <time_frame>two days</time_frame>
    <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; higher scores represent higher levels of pain, and possible side effects (drowsiness, confusion, nausea) of opioids.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numeric Rating of Scale (From 0 to 10) of Possible Sleep Disturbance of Opioids</measure>
    <time_frame>two days</time_frame>
    <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of sleep disturbance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of Fatigue at the Point of Time With Numeric Rating Scale From 0 to 10</measure>
    <time_frame>two days</time_frame>
    <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>two days</time_frame>
    <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Symptom Burden to Daily Life (by MD Anderson Symptom Inventory-Korean)</measure>
    <time_frame>two days</time_frame>
    <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of impact of symptom burden to daily life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.</description>
    <arm_group_label>Caffeine</arm_group_label>
    <other_name>Caffeine sodium benzoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced (Stage IV) cancer inpatients

          -  Adults aged over 18 years

          -  Patients who have received opioid therapy and whose pain scales are under 6 (by
             numeric rating scale)

          -  Patients who do not take caffeine beverage 48 hours before study period

          -  Volunteers who provided written informed consent

        Exclusion Criteria:

          -  Sensitivity (palpitation,headache,irritability,insomnia) to caffeine

          -  Uncontrolled hypertension and/or heart disease

          -  Liver failure (alanine aminotransferase &gt;= 100 IU/L)

          -  Kidney failure (serum creatinine &gt;= 2.0 mg/dL)

          -  Patients taken theophylline

          -  Gastroesophageal reflux disease

          -  Chronic glaucoma

          -  Cognitive impairment

          -  Progressive pain over 7 (by numeric rating scale)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Yeon Suh, M.D.,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>DongGuk University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Mercadante S, Serretta R, Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manage. 2001 May;21(5):369-72.</citation>
    <PMID>11369156</PMID>
  </reference>
  <reference>
    <citation>Manfredi PL, Gonzales GR. Symptomatic uses of caffeine in patients with cancer. J Palliat Care. 2003 Spring;19(1):63-5. Review.</citation>
    <PMID>12710118</PMID>
  </reference>
  <reference>
    <citation>Bruera E, Watanabe S. Psychostimulants as adjuvant analgesics. J Pain Symptom Manage. 1994 Aug;9(6):412-5. Review.</citation>
    <PMID>7963794</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2009</study_first_posted>
  <results_first_submitted>January 11, 2011</results_first_submitted>
  <results_first_submitted_qc>March 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2011</results_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sang-Yeon Suh</name_title>
    <organization>Dongguk University Ilsan Hospitial</organization>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Cancer patients</keyword>
  <keyword>Caffeine</keyword>
  <keyword>Adjuvant analgesics</keyword>
  <keyword>Sedation</keyword>
  <keyword>Confusion</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Sodium Benzoate</mesh_term>
    <mesh_term>Caffeine, sodium benzoate drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>42 participants were screened. 1 did not meet criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Caffeine</title>
          <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caffeine</title>
          <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.40" spread="11.76"/>
                    <measurement group_id="B2" value="67.83" spread="9.76"/>
                    <measurement group_id="B3" value="65.67" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom score</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of symptoms.</description>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25" spread="1.06"/>
                    <measurement group_id="B2" value="3.52" spread="1.12"/>
                    <measurement group_id="B3" value="3.39" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.05" spread="1.57"/>
                    <measurement group_id="B2" value="4.24" spread="1.54"/>
                    <measurement group_id="B3" value="4.15" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.20" spread="1.19"/>
                    <measurement group_id="B2" value="2.33" spread="1.23"/>
                    <measurement group_id="B3" value="2.27" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.20" spread="1.96"/>
                    <measurement group_id="B2" value="3.90" spread="1.86"/>
                    <measurement group_id="B3" value="4.05" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.55" spread="1.39"/>
                    <measurement group_id="B2" value="4.23" spread="1.51"/>
                    <measurement group_id="B3" value="4.39" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.50" spread="1.60"/>
                    <measurement group_id="B2" value="4.47" spread="1.56"/>
                    <measurement group_id="B3" value="4.49" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.95" spread="1.57"/>
                    <measurement group_id="B2" value="2.52" spread="1.50"/>
                    <measurement group_id="B3" value="2.24" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health-related quality of life</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a better health-related quality of life.</description>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.30" spread="1.34"/>
                    <measurement group_id="B2" value="4.19" spread="1.12"/>
                    <measurement group_id="B3" value="4.24" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Impact of symptom burden to daily life (by MD Anderson Symptom Inventory-Korean)</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of impact of symptom burden to daily life.</description>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Daily living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.00" spread="2.12"/>
                    <measurement group_id="B2" value="5.90" spread="1.86"/>
                    <measurement group_id="B3" value="5.46" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.90" spread="1.51"/>
                    <measurement group_id="B2" value="6.09" spread="1.33"/>
                    <measurement group_id="B3" value="6.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.25" spread="2.14"/>
                    <measurement group_id="B2" value="6.90" spread="1.64"/>
                    <measurement group_id="B3" value="6.59" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interpersonal relationship</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.80" spread="2.01"/>
                    <measurement group_id="B2" value="5.09" spread="1.54"/>
                    <measurement group_id="B3" value="4.95" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.45" spread="2.50"/>
                    <measurement group_id="B2" value="5.61" spread="1.93"/>
                    <measurement group_id="B3" value="5.05" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life enjoyment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.70" spread="1.97"/>
                    <measurement group_id="B2" value="7.66" spread="1.55"/>
                    <measurement group_id="B3" value="7.20" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids</title>
        <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; higher scores represent higher levels of pain, and possible side effects (drowsiness, confusion, nausea) of opioids.</description>
        <time_frame>two days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Caffeine</title>
            <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating of Scale (From 0 to 10) of Pain and Possible Side Effects (Drowsiness, Confusion, Nausea) of Opioids</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; higher scores represent higher levels of pain, and possible side effects (drowsiness, confusion, nausea) of opioids.</description>
          <population>intention to treat</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Symptoms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.22"/>
                    <measurement group_id="O2" value="3.10" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.92"/>
                    <measurement group_id="O2" value="3.05" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.68"/>
                    <measurement group_id="O2" value="2.20" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="1.41"/>
                    <measurement group_id="O2" value="1.80" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Fatigue at the Point of Time With Numeric Rating Scale From 0 to 10</title>
        <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of fatigue.</description>
        <time_frame>two days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Caffeine</title>
            <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Fatigue at the Point of Time With Numeric Rating Scale From 0 to 10</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of fatigue.</description>
          <population>intention to treat</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Symptoms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.88"/>
                    <measurement group_id="O2" value="3.55" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life</title>
        <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a better health-related quality of life.</description>
        <time_frame>two days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Caffeine</title>
            <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a better health-related quality of life.</description>
          <population>intention to treat</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Symptoms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="1.30"/>
                    <measurement group_id="O2" value="4.45" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Symptom Burden to Daily Life (by MD Anderson Symptom Inventory-Korean)</title>
        <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of impact of symptom burden to daily life.</description>
        <time_frame>two days</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Caffeine</title>
            <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Symptom Burden to Daily Life (by MD Anderson Symptom Inventory-Korean)</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of impact of symptom burden to daily life.</description>
          <population>intention to treat</population>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Symptoms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daily living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="2.07"/>
                    <measurement group_id="O2" value="5.95" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="1.69"/>
                    <measurement group_id="O2" value="5.60" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="1.85"/>
                    <measurement group_id="O2" value="6.75" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interpersonal relationship</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="1.79"/>
                    <measurement group_id="O2" value="4.65" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gait ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="2.36"/>
                    <measurement group_id="O2" value="5.50" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numeric Rating of Scale (From 0 to 10) of Possible Sleep Disturbance of Opioids</title>
        <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of sleep disturbance.</description>
        <time_frame>two days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caffeine</title>
            <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Rating of Scale (From 0 to 10) of Possible Sleep Disturbance of Opioids</title>
          <description>Scores were measured by Numeric Rating Scale. Scores range from 0 to 10; a higher score represents a higher level of sleep disturbance.</description>
          <units>scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Symptoms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="1.81"/>
                    <measurement group_id="O2" value="3.80" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Caffeine</title>
          <description>Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Intravenous injections of 100ml of normal saline over 1 hour</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure elevation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sang-Yeon Suh, M.D.,Ph.D</name_or_title>
      <organization>Department of Family Medicine, Dongguk University Ilsan Hospital, Republic of Korea</organization>
      <phone>0082-031-961-7490</phone>
      <email>fmmodel@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

